Navigation Links
FDA Advisers Consider New Lupus Drug
Date:11/16/2010

By Steven Reinberg
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- U.S. Food and Drug Administration advisers were weighing Tuesday whether to recommend the first new drug in more than 50 years to treat the autoimmune disease lupus.

The drug, belimumab (Benlysta), is a so-called monoclonal antibody drug developed to treat patients who suffer from systemic lupus erythematosus.

In research papers submitted to the advisory committee, the full FDA expressed some concerns about the efficacy and safety of the drug.

"I really do think the drug is efficacious," said Sandra C. Raymond, president & CEO of the Lupus Foundation of America, who was attending the advisory panel meeting. "What I'm hearing in terms of efficacy is pretty strong."

The FDA said it wants the advisory panel to look at both the efficacy data, which according to the agency is modest, and the safety data, which the agency believes raises some serious issues. Specifically, the drug has been linked to depression and suicide.

Raymond noted that many patients with lupus suffer from depression. And many patients in clinical trials testing the drug were also taking antidepressants, she added.

The advisory committee is scheduled to vote on whether the drug's risks are mitigated by the benefits it has to offer to patients who are already receiving standard care.

The agency said it is basing its concerns on the results of two phase 3 trials that compared Benlysta with a placebo.

"The risks associated with belimumab include infection, malignancy, suicidality, and overall number of deaths with a numerical imbalance that favored placebo treatment over belimumab treatment," according to the FDA.

Safety is important, Raymond said, but the drugs used to treat lupus now carry some significant side effects, too. "The safety of some of our medications is not good," she said. "So what are we comparing it to?"

The
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Advisers Back Anemia Drugs for Kidney Patients
2. FDA Advisers Consider Approval of Genetically Modified Salmon
3. FDA Advisers Weigh Approval of Genetically Modified Salmon
4. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
5. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
6. FDA to Broaden Disclosure on Advisers Conflicts of Interest
7. FDA Advisers Urge Stricter Regulation of Tanning Beds
8. Considerable proportion of patients with advanced cancer continue to undergo common cancer screening
9. ConnectedIn Divorce Resource Offers Online Expert Website for People Considering or Going Through Divorce
10. BMEGateway's 20th Anniversary Insurance Symposium considered a “Tremendous” Success
11. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Consider New Lupus Drug
(Date:7/27/2014)... (PRWEB) July 27, 2014 1-Butene is ... has good solvent properties. 1–Butene can be manufactured either ... from the reaction of ethylene. Linear alpha olefin (alkene) ... to manufacture a number of important chemicals such as ... and so on. , The 1-Butene market is extremely ...
(Date:7/27/2014)... Metachromatic leukodystrophy (MLD, also called Arylsulfatase ... is commonly listed in the family of leukodystrophies ... affects the metabolism of sphingolipids. Leukodystrophies affect the ... which acts as an insulator around nerve fibers ... involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most ...
(Date:7/27/2014)... -- Couples aren,t more likely to get divorced if ... research finds. The study only looks at trends ... a direct role in affecting whether couples stay together ... against fears that women,s growing educational advantage over men ... lead author of the study, said in an American ...
(Date:7/27/2014)... 2014 Ticket Down is a ... tickets in Miami, FL at the Sun Life Stadium ... is officially underway. In the opening game, Olympiacos from Superleague ... out to an early lead in their group. Six other ... this mini-tournament including Manchester City, Manchester United, AS Roma, Liverpool ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... a special promotion for fall meetings booked at the ... at this Downtown Denver hotel, just steps away from ... Denver’s central business district, and over 100 restaurants and ... their fall 2014 meetings at the HGI Denver will ...
Breaking Medicine News(10 mins):Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 3Health News:Stonebridge Companies’ Hilton Garden Inn Denver Downtown Announces Fall Meeting Promotion 2
... explain why C-section babies seem more likely to develop ... (HealthDay News) -- Babies who are born vaginally pick ... cesarean section, potentially affecting how their immune systems develop, ... provide more insight into why babies born through cesarean ...
... the polycystic ovary syndrome (PCOS), the most common hormone imbalance ... exposure to the chemical bisphenol A (BPA), found in many ... will be presented Sunday at The Endocrine Society,s 92nd Annual ... a known hormone disrupter, is elevated and associated with higher ...
... ... and revenues. In this Social Media Zuberance webinar we will show you how to avoid becoming ... ... (Founder and CEO of Zuberance) for a free interactive webinar at 11 AM PDT/2 ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... to Doctors, Physicians and Health Care Providers will monetize their time and streamline their patient ... the next sixty days. , ... (PRWEB) June 21, 2010 -- DocGreet.com is so sure that the services available to ...
... mental disorder affecting one in 100 people worldwide. Most cases ... and hallucinations as a teenager or adult. By that time, ... be difficult to treat. In a paper published recently ... at the University of North Carolina at Chapel Hill and ...
Cached Medicine News:Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:Women with polycystic ovary syndrome have higher BPA blood levels 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Brain signs of schizophrenia found in babies 2
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
(Date:7/24/2014)... Inc. (NYSE MKT: IG), a New Jersey based specialty generic ... the second quarter ended June 30, 2014. Second ... million in the second quarter of 2014, an increase of ... revenues of $13.3 million for the six months ended June ... in 2013 , Total revenues generated from the sale ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
... contributes to successful outcomes for your ... and technique, the materials you choose ... patients' outcomes, both short-term and long-term. ... Polyethylene. MARATHON Polyethylene is the first ...
Medicine Products: